Ryan J. MacKenzie

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Anupriya Agarwal, Ryan J. MacKenzie, Raffaella Pippa et al. · Clinical Cancer Research · 2014 · 123 citations · Full text

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML

Anupriya Agarwal, Angela G. Fleischman, Curtis L. Petersen et al. · Blood · 2012 · 41 citations

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein

Anupriya Agarwal, Ryan J. MacKenzie, Arnaud Besson et al. · Blood · 2014 · 28 citations · Full text

Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis

Thomas O’Hare, Christopher A. Eide, Anupriya Agarwal et al. · Cancer Research · 2013 · 27 citations · Full text

A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,

Anupriya Agarwal, Ryan J. MacKenzie, Jessica Oddo et al. · Blood · 2011 · 14 citations